Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
inotersen
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
tegsedi
2
×
transthyretin amyloidosis
2025
ad-comm
affimed
allogene therapeutics
amicus therapeutics
anylam pharmaceuticals
approval
apremilast
base editing
bio
biogen
biome
biotech
blueprint medicineas
boulder/denver blog main
boulder/denver top stories
briefing docs
car-t
cardiomyopathy
celgene
cervical cancer
clinical study
clinical trial
clinical trials
commissioner
crispr
crispr therapeutics
What
ago
akcea
allogene
alnylam
amyloidosis
approved
attr
available
battle
bio
cancer
crispr
debilitating
disease
diversity
drug
fda
genetic
hot
immunotherapy
investors
ipo
juno
medicines
million
nearly
new
oks
patients
pfizer
rare
remains
roundup
sets
shares
snapped
therapeutics
ticket
transthyretin
utero
Language
Current search:
tegsedi
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
